NEW YORK (GenomeWeb News) – Enzo Biochem said today that it has licensed exclusive rights to market MultiGen Diagnostics' antenatal infectious disease tests in New York and non-exclusive rights to the market them in other US territories.
Enzo will validate and seek approval for MultiGen's multiplex Antenatal Infectious Disease panel and for a thrombophilia panel after they clear New York, New Jersey, and CLIA requirements and after it secures third-party reimbursement.
New York City-based Enzo said that it hopes to make the panel available in the second half of this year.
MultiGen's antenatal panel tests for simultaneous infection of certain bacterial, viral, or fungal pathogens using one specimen. The thrombogenic panel detects multiple mutations that can detect if an individual has a genetic predisposition to blood clotting.
MultiGen's DNA sequencing-based technology increases the "accuracy and utility" of its diagnostic tests, MultiGen Founder and President T. Vinayagamoorthy said in a statement.
Financial terms of the agreement were not released.